AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$MIRM

Howe Jolanda sold $66K of MIRM

Howe Jolanda (SVP, GLOBAL CONTROLLER) sold 658 shares of Mirum Pharmaceuticals, Inc. (MIRM) at $100.00 on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Howe Jolanda
Published Sep 3, 2026, 10:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MIRM
Bearish
high confidence
Mentioned
$MIRM
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MIRMBearishLow
01

Why it matters

The disclosed sale is modest and unlikely to affect market perception significantly.

02

Market read

Routine insider sale with minimal trading relevance.

03

What to watch

Potential upcoming clinical data releases that could amplify the effect of any insider trading.

Relevance 2/10Novelty 2/10Timing: post‑market 2026‑09‑02 filing

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$MIRMBearishHigh confidence
Context

SVP Howe Jolanda sold 658 shares of Mirum Pharmaceuticals for $65,800 via a 10b5-1 plan, reducing his holding to 616 shares.

Expected impact

Minor dip or flat price action; no material impact.

Evidence & confidence

The transaction size ($66K) is trivial relative to market cap; insider sales of this magnitude rarely move the price.

Market effects

Sector

No broader sector impact; mirrors routine insider activity in biotech.

Regional

Limited to U.S. investors tracking Mirum.

Global

None

Counterpoint

What could challenge this read

If the insider is reducing exposure ahead of negative news, the stock could face a sharper sell‑off.

Key entities

  • Company
    Mirum Pharmaceuticals, Inc.

    Biopharmaceutical company developing treatments for metabolic diseases.

  • Insider
    Howe Jolanda

    Senior Vice President, Global Controller at Mirum.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MIRM insider trading history →

Related articles

NOV 2
$MIRMHighAI 8/10

Mirum will present longer-term hepatitis D response data, including in people with cirrhosis.

Mirum Pharmaceuticals will present data on its hepatitis D treatment, brelovitug, at The Liver Meeting 2026, including Phase 3 results and longer-term efficacy in patients with cirrhosis. The company will also share additional analyses on volixibat for primary sclerosing cholangitis (PSC) and new evidence on LIVMARLI (maralixibat) for rare cholestatic liver diseases.

stocktitan.net3 min
OCT 26
$MIRMMedAI 8/10

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals (MIRM) reported positive results from Cohort 2 of the PROGRESS study for ATEBRIOZ (zilurgisertib) in pediatric FOP patients aged 6 to <12. The drug reduced HO lesion volume and improved joint mobility, with no new lesions. Mirum plans an sNDA submission in H1 2027 to expand the indication. Safety findings were consistent with prior data.

financialcontent.com2 min
OCT 26
$MIRMHighAI 9/10

Mirum Pharmaceuticals Reports Positive Pediatric ATEBRIOZ Study Results

Mirum Pharmaceuticals reported positive results from a pediatric study of ATEBRIOZ, showing reduced heterotopic ossification and improved joint mobility in children aged 6 to under 12 with FOP. At Week 24, lesion volume decreased by 8.09 cm³ with zilurgisertib and increased by 9.14 cm³ with placebo. The company plans to submit an sNDA in the first half of 2027 for expanded use.

tradingview.com1 min
OCT 26
$MIRMMedAI 9/10

Mirum Pharmaceuticals, Inc. (MIRM): Announcement of Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with…

Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Announcement of Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva On October 26, 2026, Mirum Pharmaceuticals, Inc. (the “Company”)

SEC EDGAR 8-K2 min